Prime Medicine, Inc. (PRME)
| Market Cap | 760.28M +15.4% |
| Revenue (ttm) | 7.06M +18.1% |
| Net Income | -176.35M |
| EPS | -0.99 |
| Shares Out | 214.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,134,377 |
| Open | 3.700 |
| Previous Close | 3.840 |
| Day's Range | 3.490 - 3.940 |
| 52-Week Range | 2.670 - 5.910 |
| Beta | 2.15 |
| Analysts | Strong Buy |
| Price Target | 7.39 (+108.06%) |
| Earnings Date | Nov 12, 2026 |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in... [Read more]
Financial Performance
In 2025, Prime Medicine's revenue was $4.63 million, an increase of 55.28% compared to the previous year's $2.98 million. Losses were -$201.14 million, 2.69% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PRME stock is "Strong Buy." The 12-month stock price target is $7.39, which is an increase of 108.06% from the latest price.
News
Prime Medicine Transcript: Jefferies Global Healthcare Conference
Wilson disease dosing is underway, with a fuller data update expected in 2027; Alpha-1 first-patient dosing is targeted for year-end 2026 or soon after. Key goals include CGD approval and Wilson and Alpha-1 data in 2027.
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine reports Q3 EPS (22c), consensus (24c)
Reports Q3 revenue $4.21M, consensus $1.08M. “Prime Medicine (PRME) continued to make significant progress this quarter, highlighted by dosing the first patient in our Phase 1/2 trial of PM577a for…
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected ...
Prime Medicine Quarterly report: Q3 2026
Prime Medicine has published its Q3 2026 quarterly earnings report on November 12, 2026.
Prime Medicine Earnings release: Q3 2026
Prime Medicine released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Cathie Wood’s ARK Investment buys 1.74M shares of Prime Medicine today
20:10 EST Cathie Wood’s ARK Investment buys 1.74M shares of Prime Medicine (PRME) today
Prime Medicine 35.7M share Spot Secondary priced at $3.50
The deal range is $3.50-$3.60. Jefferies, TD Cowen and Goldman Sachs acted as joint book running managers for the offering.
Prime Medicine Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine $125M Spot Secondary; price range $3.50-$3.60
Jefferies, TD Cowen and Goldman Sachs are acting as joint book running managers for the offering.
Prime Medicine announces $125M common stock offering
Prime Medicine (PRME) announced that it has commenced an underwritten public offering of $125M of shares of its common stock. All of the shares of common stock in the proposed…
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine to Present at Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of Units
MONTREAL--(BUSINESS WIRE)--Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate ...
Prime Medicine doses first patient in PM577a trial
Prime Medicine (PRME) announced that the first patient has been dosed in the company’s global Phase 1/2 clinical trial of PM577a, an investigational in vivo Prime Editor for H1069Q-mutated Wilson…
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutatio...
Prime Medicine Slides: Corporate presentation
Prime Medicine has posted slides in relation to its latest quarterly earnings report, which was published on October 4, 2026.
Prime Medicine announces FDA clearance of IND application for PM647
Prime Medicine (PRME) announced that the FDA has cleared the company’s Investigational New Drug, or IND, application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficien...
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected i...
Prime Medicine Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Prime Editing technology enables versatile and safer gene editing, with ongoing clinical programs in Wilson’s disease and AATD targeting broad patient populations. Regulatory flexibility and efficient delivery platforms support rapid development, with proof-of-concept data expected in 2027 for key programs.
Prime Medicine Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Prime Editing offers broad, precise, and safe genome editing, with clinical progress in CGD, Wilson disease, and Alpha-1 programs. Regulatory flexibility and platform synergies support rapid expansion, while a strong cash position extends runway into 2027.
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap...
Prime Medicine transferred with Buy rating at Chardan
Chardan analyst Keay Nakae keept a Buy rating on Prime Medicine (PRME) with a $7 price target following a transfer of coverage. The firm cites the potential of the company’s…
BMO starts Prime Medicine at Outperform into 2027 readouts
BMO Capital analyst David Lebowitz initiated coverage of Prime Medicine (PRME) with an Outperform rating and $9 price target The firm views Prime as a “differentiated” next-generation gene editing pla...
Prime Medicine initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Prime Medicine (PRME) with an Outperform rating and $9 price target BMO rolled out coverage on nine biotechnology companies, saying each might be considered a…